Hsyu PH - Search Results

1

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.

Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. Ribas A, et al. Among authors: hsyu ph. J Transl Med. 2012 Nov 21;10:236. doi: 10.1186/1479-5876-10-236. J Transl Med. 2012. PMID: 23171508 Free PMC article. Clinical Trial.

2

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA. Daud AI, et al. Among authors: hsyu ph. Clin Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16. Clin Cancer Res. 2012. PMID: 22179664 Clinical Trial.

3

Population pharmacokinetic and pharmacodynamic analysis of bosutinib.

Hsyu PH, Mould DR, Abbas R, Amantea M. Hsyu PH, et al. Drug Metab Pharmacokinet. 2014;29(6):441-8. doi: 10.2133/dmpk.DMPK-13-RG-126. Epub 2014 Jun 10. Drug Metab Pharmacokinet. 2014. PMID: 24919837 Free article. Retracted. Clinical Trial.

4

Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.

Abbas R, Hsyu PH. Abbas R, et al. Among authors: hsyu ph. Clin Pharmacokinet. 2016 Oct;55(10):1191-1204. doi: 10.1007/s40262-016-0391-6. Clin Pharmacokinet. 2016. PMID: 27113346 Review.

5

Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.

Ono C, Hsyu PH, Abbas R, Loi CM, Yamazaki S. Ono C, et al. Among authors: hsyu ph. Drug Metab Dispos. 2017 Apr;45(4):390-398. doi: 10.1124/dmd.116.074450. Epub 2017 Feb 6. Drug Metab Dispos. 2017. PMID: 28167538

6

Retraction notice to "Population pharmacokinetic and pharmacodynamic analysis of bosutinib" [Drug Metab Pharmacokinet 29 (2014) 441-448].

Hsyu PH, Mould DR, Abbas R, Amantea M. Hsyu PH, et al. Drug Metab Pharmacokinet. 2019 Apr;34(2):163. doi: 10.1016/j.dmpk.2019.01.003. Epub 2019 Feb 10. Drug Metab Pharmacokinet. 2019. PMID: 30922682

7

Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.

Hsyu PH, Mould DR, Upton RN, Amantea M. Hsyu PH, et al. Cancer Chemother Pharmacol. 2013 Jan;71(1):209-18. doi: 10.1007/s00280-012-1998-4. Epub 2012 Oct 16. Cancer Chemother Pharmacol. 2013. PMID: 23070145

8

Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.

Hsyu PH, Pignataro DS, Matschke K. Hsyu PH, et al. Eur J Clin Pharmacol. 2017 Jan;73(1):49-56. doi: 10.1007/s00228-016-2108-z. Epub 2016 Oct 7. Eur J Clin Pharmacol. 2017. PMID: 27718000 Clinical Trial.

9

Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.

Hsyu PH, Pignataro DS, Matschke K. Hsyu PH, et al. Clin Pharmacol Drug Dev. 2018 May;7(4):373-381. doi: 10.1002/cpdd.396. Epub 2017 Oct 23. Clin Pharmacol Drug Dev. 2018. PMID: 29058816 Clinical Trial.

10

Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.

Hsyu PH, Pignataro DS, Matschke K. Hsyu PH, et al. Eur J Clin Pharmacol. 2017 Jan;73(1):57-63. doi: 10.1007/s00228-016-2115-0. Epub 2016 Oct 7. Eur J Clin Pharmacol. 2017. PMID: 27717999 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page